Common Contracts
4 similar Underwriting Agreement contracts by Zosano Pharma Corp, Adlai Nortye Ltd., Zevra Therapeutics, Inc.
ZEVRA THERAPEUTICS, INC. 9,230,770 Shares of Common Stock (par value $0.0001 per share) Underwriting AgreementUnderwriting Agreement • August 9th, 2024 • Zevra Therapeutics, Inc. • Pharmaceutical preparations • New York
Zevra Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 9,230,770 shares of its common stock (the “Common Stock”), par value $0.0001 per share (the “Shares”). The 9,230,770 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 1,384,615 Shares pursuant to such option are collectively called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Cantor Fitzgerald & Co. (“Cantor”) and William Blair & Company, L.L.C. (“William Blair”) have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Sc
ADLAI NORTYE LTD. [ · ] American Depositary Shares Representing [ · ] Ordinary Shares (par value $0.0001 per share) Underwriting AgreementUnderwriting Agreement • August 14th, 2023 • Adlai Nortye Ltd. • Pharmaceutical preparations • New York
ZOSANO PHARMA CORPORATION 51,250,000 Shares of Common Stock and Series F Warrants to Purchase 51,250,000 Shares of Common Stock (par value $0.0001 per share) Underwriting AgreementUnderwriting Agreement • February 9th, 2022 • Zosano Pharma Corp • Pharmaceutical preparations • New York
Zosano Pharma Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to Maxim Group LLC (the “Underwriter”) (i) an aggregate of 51,250,000 shares (the “Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”) and (ii) Series F Warrants of the Company, in the form set forth in Exhibit B hereto, to purchase shares of Common Stock (the “Warrants”). Each Share is being sold together with one Warrant; and each full Warrant is exercisable for one Share at an exercise price of $0.30 per whole share. The 51,250,000 Shares and 51,250,000 Warrants to be sold by the Company are referred to as the “Firm Securities.” In addition, the Company has granted to the Underwriter an option to purchase up to an additional 7,687,500 Shares (together with the Shares, the “Offered Shares”) and 7,687,500 Warrants as provided in Section 2. The additional 7,687,500 Shares and 7,687,500 Warrants to be sold by the Company pursuant to such option are collectively called
ZOSANO PHARMA CORPORATION 15,937,130 Shares of Common Stock (par value $0.0001 per share) Underwriting AgreementUnderwriting Agreement • September 3rd, 2020 • Zosano Pharma Corp • Pharmaceutical preparations • New York
Zosano Pharma Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to BTIG, LLC (“BTIG”) an aggregate of 15,937,130 shares (the “Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”). The 15,937,130 Shares to be sold by the Company are called the “Offered Shares.”
